Under construction – not a live service
Sign in
Not yet taking people in GermanyNo phase

Cloud software guides cholesterol-lowering treatment after heart attack

Tests software-guided intensive cholesterol-lowering drugs in adults after heart attack.

Key facts

Who runs it
Jena University Hospital
Where
Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg, Jena, Leipzig, and Regensburg, GermanySee the 10 sites
Trial code
Registry title
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
Status
Not yet recruiting
People taking part
300 people, planned
Started
1 Apr 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
Record updated
7 March 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 who had a heart attack, either ST-elevation or non-ST-elevation. It tests cholesterol-lowering treatment guided by a cloud-based software system.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
A heart attack: either ST-elevation (STEMI) or non-ST-elevation (NSTEMI) myocardial infarction.
Earlier treatment
People already taking cholesterol-lowering medicines when they arrive at the hospital cannot join.

Main reasons for not taking part

  • No informed consent
  • In cardiogenic shock
  • Cannot take cholesterol-lowering therapy for medical reasons
  • Already on cholesterol-lowering medicines when admitted

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • patients with ST- and Non-ST-elevation myocardial infarctions

Who cannot take part

  • patients with contraindication to lipid-lowering therapy
  • patients on lipid-lowering medications on admission
  • patient without informed concent
  • patients in cardiogenic shock

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in Germany

  • Universitätsmedizin BerlinBerlin, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum DresdenDresden, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum EssenEssen, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum FrankfurtFrankfurt, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum FreiburgFreiburg im Breisgau, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum HalleHalle, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • Universitätsklinikum des SaarlandesHomburg, GermanyContact: Oliver Weingärter, MDNo longer taking part
  • University Hospital JenaJena, GermanyContact: Oliver Weingaertner, MDNo longer taking part
  • Universitatsklinikum LeipzigLeipzig, GermanyContact: Ulrich Laufs, MDNo longer taking part
  • Universitätsklinikum RegensburgRegensburg, GermanyContact: Oliver Weingärter, MDNo longer taking part

About the trial

What the trial wants to find out

Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).

The 2 groups in the trial

  • Cloud-based softwareExisting treatment, for comparison

    cloud-based software system (CLIMEDO GmbH) will support patients in ESC/EAS LDL-C target attainment (\< 55mg/dl/1.4 mol/L)

    Treatment: statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran

  • Standard CarePlacebo, for comparison

    Patients will be treated by general practitioners (GPs) after hospital discharge. The discharge letter will recommend ESC/EAS dyslipidemia LDL-cholesterol targets (\< 55mg/dl/1.4 mol/L)

    Treatment: statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
"Intensive Lipid-Lowering Therapy Guided by a Cloud-based Software System (CLIMEDO GmbH) in Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarctions" (Germany on Target)
Plain-language title
Cloud software guides cholesterol-lowering treatment after heart attackGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05587621, who can take part
Record updated
7 March 2024